Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine?

<table>Result of risk of bias assessment for included studies.</table>

Malaria Research and Treatment

fig2

Figure 2

Figure 2: Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine? 

Figure 2 | Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? 